United Therapeutics Urges Final Patent Win After Liquidia Denial

United Therapeutics Corp. urged a Delaware federal court to finalize its September 2022 victory in a patent dispute over rival lung-disease drugs, after the US Supreme Court on Tuesday rejected Liquidia Corp.’s related petition for review.

UTC said the court’s final judgment finding Liquidia’s proposed Yutrepia infringes US Patent No. 10,716,793” and upholding the patent’s validity “is now final beyond the possibility of all appellate review,” according to UTC’s letter to Judge Richard G. Andrews filed Tuesday in the US District Court for the District of Delaware.

• Liquidia urged the judge in another Tuesday letter to maintain the stay ...